Posts

Posted on

NEWTON GOLF Company Appoints Ryan Stearns as Chief Financial Officer

CAMARILLO, CA, Jan. 06, 2025 (GLOBE NEWSWIRE) —

NEWTON GOLF Company
 (Nasdaq: SPGC) (“NEWTON GOLF” or the “Company”), a technology-forward golf company with a growing portfolio of golf products, including putters, golf shafts, golf grips, and other golf-related accessories, announces the appointment of Ryan Stearns as Chief Financial Officer (CFO). Stearns brings over two decades of financial expertise spanning the public and private sectors, with a proven track record of driving operational excellence, strategic growth, and financial innovation.

Stearns will oversee the Company’s financial strategy, operational reporting, and technology integration to support the brand’s continued growth and global expansion. His extensive experience in mergers and acquisitions, capital funding, and financial process optimization positions him to make an immediate impact.

Throughout his career, Stearns has held impactful financial leadership roles in both established companies and growth-focused organizations. Most recently, he served as CFO of a professional consulting firm specializing in healthcare, fintech, and SaaS, where he secured $130 million in financing and successfully guided the company through its first financial audit. Prior to that role, Stearns served as the CFO of a life science company, where he managed a diverse biotech portfolio and helped scale the company from a $12 million startup to a $500 million valuation. Earlier in his career, as CFO of a large business service company, Stearns led a $185 million acquisition and implemented cost-saving initiatives that delivered $5 million in annual cost savings.

“Ryan’s appointment as CFO is well timed to our expected expansion of our financial performance in 2025 through increased brand recognition of our innovative replacement shafts and putters,” said Greg Campbell, CEO of NEWTON GOLF Company. “His expertise and leadership will be instrumental in driving rapid business growth, and his background in M&A brings an important skill set to this stage of the Company.”

All of NEWTON GOLF products can be found on www.newtongolfco.com.


About NEWTON GOLF: A Sacks Parente Company

NEWTON GOLF: A Sacks Parente Company, is a technology-forward golf company that help golfers elevate their game. With a growing portfolio of golf products, including putters, golf shafts, golf grips, and other golf-related accessories, the Company’s innovative accomplishments include: the First Vernier Acuity putter, patented Ultra-Low Balance Point (ULBP) putter technology, weight-forward Center-of-Gravity (CG) design, and pioneering ultra-light carbon fiber putter shafts.

In consideration of its growth opportunities in golf shaft technologies, the Company expanded its manufacturing business in April of 2022 to develop the advanced Newton brand of premium golf shafts by opening a new shaft manufacturing facility in St. Joseph, MO. It is the Company’s intent to manufacture and assemble substantially all products in the United States, while also expanding into golf apparel and other golf-related product lines to enhance its growth.

The Company’s future expansions may include broadening its offerings through mergers, acquisitions or internal developments of product lines that are complementary to its premium brand. The Company currently sells its products through resellers, the Company’s websites, Club Champion retail stores, and distributors in the United States, Japan, and South Korea. For more information, please visit the Company’s website at www.newtongolfco.com or on social media at @newtongolfco.com, @newtonshafts, or @gravityputters.

Media Contact for NEWTON GOLF:

Beth Gast
BG Public Relations
[email protected]

Investor Contact for NEWTON GOLF:

CORE IR
516-222-2560
[email protected]



Posted on

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Vancouver, Canada, Jan. 06, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a European patent application with the European Patent office for its innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.

The patent application refers to Clearmind’s successful collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA).

Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, “To date, we have filed 13 patents in the US and in several other global jurisdictions related to our collaboration with SciSparc. As acceptance of psychedelic therapies continues to grow within the medical community, building a robust intellectual property portfolio establishes Clearmind as a pioneer and leader in the next generation of treatments for binge behavior.”

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information visit: https://www.clearmindmedicine.com or contact:

Investor Relations
[email protected]

Telephone: (604) 260-1566
US: [email protected]

General Inquiries


[email protected]


www.Clearmindmedicine.com

About SciSparc Ltd.

SciSparc Ltd. (SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses
acceptance of psychedelic therapies continu
ing
to grow within the medical community
and how
building a robust intellectual property portfolio establishes Clearmind as a pioneer and leader in the next generation of treatments for binge behavior
. The Company cannot assure that any patent will issue
as a result of
a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited
to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be
drawn
that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.



Posted on

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 11:15 a.m. Pacific Time in San Francisco, CA.

The presentation will be broadcast live and archived on the Company’s website at www.profoundmedical.com under “Webcasts” in the Investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.


Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma; and the success of Profound’s U.S. commercialization strategy and activities for TULSA-PRO

®

. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

For further information, please contact:

Stephen Kilmer
Investor Relations
[email protected]
T: 647.872.4849

Susan Thomas
Public Relations
[email protected]
T: 619.540.9195



Posted on

Sonida Announces Latest Asset Acquisition and Closing of Fannie Mae Maturity Modifications

Sonida Announces Latest Asset Acquisition and Closing of Fannie Mae Maturity Modifications

Completes purchase of recently built senior living community in Cincinnati for $16.3 million with favorable financing terms

Brings total 2024 acquired properties to 20 and total operating portfolio to 94 communities

Completes previously disclosed Fannie Mae loan modification extending maturities on $220 million of mortgage loans from December 2026 to January 2029

DALLAS–(BUSINESS WIRE)–
Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in senior living communities, announced today the closing of its latest acquisition, as the Company continues to execute on its inorganic, accretive growth strategy, which aims to further expand and upgrade its portfolio to fully leverage operating scale and efficiencies.

“Sonida ended the year with two additional transactions further positioning the company for success in 2025 and beyond. The Company continues to execute on its growth strategy through creative deal structuring and expansion of its best-in-class operating platform to aggressively and strategically invest in high-quality communities at exceptionally attractive valuations,” said Brandon Ribar, President and Chief Executive Officer. “With significant operational upside remaining in our current portfolio, a strong pipeline, and no material debt maturities on the horizon, we look forward to delivering on our commitment to accretive and sustainable growth with resident care and service at the center of our efforts.”

Capital Allocation – Senior Housing Community Acquisition in the Midwest

On December 31, 2024, the Company finalized the acquisition of a single senior living community located in Cincinnati, OH. Construction on the upscale and amenitized asset was completed in 2021; however, the community never opened due to foreclosure on the construction borrower. Sonida’s purchase price of $16.3 million, or approximately $198,000 per unit, reflects a significant discount to the original total construction cost, aligning with Sonida’s focus on acquiring high quality real estate at meaningful discounts to replacement cost.

The community is strategically situated directly adjacent to Sonida’s existing Wellington at North Bend Crossing community (“Wellington”), a highly occupied and high-performing asset. The new property’s 82 units (50 Assisted Living / 32 Memory Care) when combined with the Wellington’s existing footprint, creates a unique densification opportunity for Sonida. The two-asset “campus” with 203 units collectively, will provide a full continuum of care and broader range of services to residents, further leveraging operating scale through cost efficiencies in an attractive and under-supplied market. Consistent with the Company’s strategy of regional densification, the acquisition brings Sonida’s greater Cincinnati portfolio total to five assets.

Sonida funded the transaction with $18.25 million of seller-financing, including $2.0 million for capital expenditure investment into the facility (i.e. primarily FFE), which is expected to be utilized prior to the targeted mid-2025 opening. The non-recourse mortgage carries an 84-month term and 24-month interest waiver to support lease-up and stabilization, with a 3% fixed interest-only rate thereafter.

Proactive Debt Management – Completed Fannie Mae Loan Extension

In December 2024, the Company consummated the previously announced maturity extension of 18 individual mortgages (representing $220.1 million of debt outstanding as of September 30, 2024) from December 1, 2026 to January 1, 2029. As part of the modification, the Company funded a $2 million principal paydown at closing and will fund three additional principal paydowns in November 2025 ($2 million), November 2026 ($3 million) and November 2027 ($3 million). The mortgages, which are interest-rate only through maturity, carry a blended interest rate of 4.35% which will remain unchanged for the duration of the loans. As a result of this extension, the Company has no significant debt maturities until 2027.

Safe Harbor

The forward-looking statements in this press release, including, but not limited to, statements relating to the Company’s acquisitions, are subject to certain risks and uncertainties that could cause the Company’s actual results and financial condition to differ materially, including, but not limited to the Company’s ability to recognize the anticipated benefits of such acquisitions; the impact of such acquisitions on the Company’s business, including our ability to successfully implement integration strategies or achieve expected synergies and operating efficiencies; any legal proceedings that may be brought related to such acquisitions; our projections related to said acquisitions may not materialize as expected; and other risks and factors identified from time to time in the Company’s reports filed with the SEC, including the Company’s ability to generate sufficient cash flows from operations, proceeds from equity issuances and debt financings, and proceeds from the sale of assets to satisfy its short- and long-term debt obligations and to fund the Company’s acquisitions and capital improvement projects to expand, redevelop, and/or reposition its senior living communities; increases in market interest rates that increase the cost of certain of our debt obligations; increased competition for, or a shortage of, skilled workers, including due to general labor market conditions, along with wage pressures resulting from such increased competition, low unemployment levels, use of contract labor, minimum wage increases and/or changes in overtime laws; the Company’s ability to obtain additional capital on terms acceptable to it; the Company’s ability to extend or refinance its existing debt as such debt matures; the Company’s compliance with its debt agreements, including certain financial covenants, and the risk of cross-default in the event such non-compliance occurs; the Company’s ability to complete acquisitions and dispositions upon favorable terms or at all, including the possibility that the expected benefits and our projections related to such acquisitions may not materialize as expected; the risk of oversupply and increased competition in the markets which the Company operates; the Company’s ability to improve and maintain controls over financial reporting and remediate the identified material weakness discussed in its recent Quarterly and Annual Reports filed with the SEC; the cost and difficulty of complying with applicable licensure, legislative oversight, or regulatory changes; risks associated with current global economic conditions and general economic factors such as inflation, the consumer price index, commodity costs, fuel and other energy costs, competition in the labor market, costs of salaries, wages, benefits, and insurance, interest rates, and tax rates; the impact from or the potential emergence and effects of a future epidemic, pandemic, outbreak of infectious disease or other health crisis; and changes in accounting principles and interpretations.

About Sonida

Dallas-based Sonida Senior Living, Inc. is a leading owner, operator and investor in independent living, assisted living and memory care communities and services for senior adults. The Company provides compassionate, resident-centric services and care as well as engaging programming operating 94 senior housing communities in 20 states with an aggregate capacity of over 10,000 residents, including 81 communities which the Company owns (including eight communities in which the Company owns varying interests through two separate joint ventures), and 13 communities that the Company manages on behalf of a third-party.

For more information, visit www.sonidaseniorliving.com or connect with the Company on Facebook, X or LinkedIn. 

Investor Relations

Jason Finkelstein

IGNITION IR

[email protected]  

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Seniors Construction & Property Managed Care Health Consumer Other Health Residential Building & Real Estate

MEDIA:

Logo
Logo
Posted on

WiSA Association Announces Groundbreaking Innovations for Wireless Audio at CES 2025

WiSA Association Announces Groundbreaking Innovations for Wireless Audio at CES 2025

WiSA E-based Reference Designs, Cutting-Edge Mobile Apps, and the Revolutionary SoundSend E Take Center Stage at CES 2025

BEAVERTON, Ore.–(BUSINESS WIRE)–
WiSA Association, a subsidiary of WiSA Technologies, Inc. (“WiSA Technologies,” “WiSA” or the “Company”) (NASDAQ: WISA), which anticipates closing its acquisition of Datavault® intellectual property and information technology assets of privately held Data Vault Holdings Inc.® and changing its name to Datavault Inc. and ticker symbol to ADIO in January 2025, announces the launch of three innovative reference designs, three new mobile applications, and the SoundSend E transmitter in 2025. These technologies are designed to offer partner brands and consumers greater versatility, increased functionality, and enhanced ease of implementation and use. WiSA will demonstrate these groundbreaking innovations at its CES suite at the Venetian.

Next-Generation Reference Designs for Wireless Audio Based on WiSA E Technology

WiSA will debut its newly developed WiSA E-based reference designs: the “Player1” wireless audio transmitter platform, the “Dragon” powered receiver platform, and the “Pegasus” passive receiver platform. These reference designs empower WiSA Association members to quickly and efficiently create branded wireless audio products, expand their product offerings, or bring legacy systems into the wireless home theater ecosystem.

“Our goal is to help brands bring exciting new solutions to market,” said Tony Ostrom, president of the WiSA Association. “These platforms simplify connectivity and interoperability, making it easier to integrate legacy products and develop innovative audio systems.”

  • Player1: A streamlined transmitter reference design that connects to modern TVs via HDMI and wirelessly transmits decoded PCM audio to WiSA E-certified speakers.
  • Dragon and Pegasus: Powered and passive wireless receiver platforms designed for compatibility with a variety of speaker types to create wireless multi\channel audio systems.

All three reference designs feature WiSA E technology for seamless certification and interoperability, supporting any WiSA E-certified component and integrating effortlessly with the WiSA Connect app for enhanced control and management.

Revolutionary Mobile Apps for Certification, Connection, and Management

To further enhance the WiSA E ecosystem, WiSA is launching three cutting-edge mobile applications:

  • WiSA Certification App: Streamlines product development and certification for WiSA E technology, ensuring seamless interoperability.
  • WiSA Express App: Simplifies the connection of TVs and other sources to WiSA E-certified speakers, making TVs the centerpiece of the home entertainment system.
  • WiSA Connect App: Manages device setup, system configuration, and user control, including the new SoundSend E transmitter.

“Our apps make system setup, device control, and certification processes more intuitive than ever,” Ostrom said. “These tools are designed to simplify every aspect of the WiSA E experience for both consumers and industry partners.”

SoundSend E: The Future of Wireless Audio

WiSA also unveiled the SoundSend E, a groundbreaking successor to its award-winning wireless audio transmitter. Built on WiSA E technology, SoundSend E introduces expanded connectivity, Dolby Atmos decoding, and integration with the WiSA Connect app for a seamless user experience.

“With full audio system set-up and control, enhanced DSP, and Bluetooth audio input, SoundSend E redefines wireless home audio,” Ostrom said. “SoundSend E offers unparalleled versatility and performance for connecting modern TVs to WiSA E-certified speakers.”

Key features include:

  • Connectivity: HDMI ARC/eARC, optical, and Bluetooth audio inputs.
  • Performance: Upgraded DSP for superior audio quality.
  • Ease of Use: Automatic detection of WiSA E-certified speakers and integration with the WiSA Connect app for unified control.

WiSA at CES 2025

WiSA Technologies and the WiSA Association will showcase all these innovations at CES 2025, taking place from January 7–10 at their suite at Venetian. Attendees can experience live demonstrations of the WiSA E platforms, mobile apps, SoundSend E, and new products featuring WiSA E technology.

For more information or to schedule a meeting, contact:

To learn more about WiSA and explore its product offerings, visit www.wisatechnologies.com.

About WiSA Association

WiSA® educates, evangelizes, and promotes solutions for spatial audio in the home. Working in collaboration with technology developed by WiSA Technologies Inc., WiSA Association engages with leading consumer electronics companies, technology providers, retailers, and ecosystem partners to make immersive audio an experience everyone can enjoy. WiSA, LLC, which operates the Wireless Speaker and Audio Association, is a wholly-owned subsidiary of WiSA Technologies Inc. For more information about WiSA, please visit: www.wisatechnologies.com.

About WiSA Technologies, Inc

WiSA Technologies, Inc. (NASDAQ: WISA) is the developer of spatial, wireless sound technology for smart devices and next-generation home entertainment systems marketed under the WiSA brands. WiSA’s technology delivers immersive audio experiences for high-definition content, including movies and video, music, sports, gaming/esports, and more. Headquartered in Beaverton, OR, WiSA has sales teams in Taiwan, China, Japan, Korea and California. For more information, please visit: www.wisatechnologies.com.

About Data Vault Holdings Inc.

Data Vault Holdings Inc. is a technology holding company that provides a proprietary, cloud-based platform for the delivery of blockchain objects. Data Vault Holdings Inc. provides businesses with the tools to monetize data assets securely over its Information Data Exchange® (IDE). The company is in the process of finalizing the consolidation of its affiliates Data Donate Technologies, Inc., ADIO LLC, and Datavault Inc. as wholly owned subsidiaries under one corporate structure. Learn more about Data Vault Holdings Inc. Datavault Inc. and True Luck, Inc. as wholly owned subsidiaries under one corporate structure. Learn more about Data Vault Holdings Inc. at www.datavaultsite.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, include, among others, the Company’s and Data Vault Holdings, Inc.’s expectations with respect to the closing of its proposed asset purchase between them (the “DataVault Asset Purchase”), the timing of the Company’s name change, the Company’s and CSI’s expectations with respect to the proposed acquisition of CSI by the Company (the “Acquisition”), including statements regarding the benefits of the Acquisition, the anticipated timing of the Acquisition, the implied valuation of CSI, the products offered by CSI and the markets in which it operates, and the Company’s and CSI’s projected future results and market opportunities, as well as information with respect to WiSA’s future operating results and business strategy. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of a variety of factors, including, but not limited to: (i) risks and uncertainties impacting WiSA’s business including, risks related to its current liquidity position and the need to obtain additional financing to support ongoing operations, WiSA’s ability to continue as a going concern, WiSA’s ability to maintain the listing of its common stock on Nasdaq, WiSA’s ability to predict the timing of design wins entering production and the potential future revenue associated with design wins, WiSA’s ability to predict its rate of growth, WiSA’s ability to predict customer demand for existing and future products and to secure adequate manufacturing capacity, consumer demand conditions affecting WiSA’s customers’ end markets, WiSA’s ability to hire, retain and motivate employees, the effects of competition on WiSA’s business, including price competition, technological, regulatory and legal developments, developments in the economy and financial markets, and potential harm caused by software defects, computer viruses and development delays, (ii) risks related to the DataVault Asset Purchase, including WiSA’s ability to close the Asset Purchase in a timely manner or at all, or on the terms anticipated, whether due to WiSA’s ability to satisfy the applicable closing or otherwise, as well as risks related to WiSA’s ability to realize some or all of the anticipated benefits from the DataVault Asset Purchase, (iii) risks related to the Acquisition, including WiSA’s ability to close the Acquisition in a timely manner or at all, or on the terms anticipated, whether due to WiSA’s ability to satisfy the applicable closing or otherwise, as well as risks related to WiSA’s ability to realize some or all of the anticipated benefits from the Acquisition, any risks that may adversely affect the business, financial condition and results of operations of CSI, including but not limited to cybersecurity risks, the potential for AI design and usage errors, risks related to regulatory compliance and costs, potential harm caused by data privacy breaches, digital business interruption and geopolitical risks, and (iv) other risks as set forth from time to time in WiSA’s filings with the U.S. Securities and Exchange Commission. The information in this press release is as of the date hereof and neither the Company nor CSI undertakes any obligation to update such information unless required to do so by law. The reader is cautioned not to place under reliance on forward looking statements. Neither the Company nor CSI gives any assurance that either the Company or CSI will achieve its expectations.

Investors:

David Barnard, Alliance Advisors Investor Relations, 415-433-3777, [email protected]

KEYWORDS: Oregon United States North America

INDUSTRY KEYWORDS: Audio/Video Hardware TV and Radio Consumer Electronics Technology Apps/Applications Mobile/Wireless Entertainment

MEDIA:

Logo
Logo
Posted on

Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that it had appointed Norman Staskey as Chief Financial Officer.

Mr. Staskey has worked for Danforth Advisors since 2021, working as Chief Financial Officer for clients such as Azitra, Inc., a biotechnology company developing novel dermatology therapeutic technologies. Norm has over 25 years working in capital market and M&A transactions most recently as a Managing Director in EY’s (formally Ernst & Young) national transactions practice where he led or advised on several fortune 500 M&A deals for both domestic and cross-border transactions, and was involved in the merger of Dell Inc. and EMC Corporation as a member of the EY team. Norm has also worked on several recent M&A deals in the biotech industry.

“We are excited to welcome Norm to the Organovo team,” said Keith Murphy, Executive Chairman. “With his extensive experience, including focus in the biotech industry, and his strong background in M&A transactions, he brings a skill set that opens up new possibilities for Organovo in 2025.”

In November, the liver fibrosis treatment potential of Organovo’s lead drug FXR314, was highlighted in a presentation of Phase 2 results in Metabolic Dysfunction-Associated Steatohepatitis (MASH). Dr. Eric Lawitz shared the complete details of the 16-week, randomized, placebo-controlled, multi-center Phase 2 study of FXR314 in MASH patients at the Liver Meeting (November 15-19, San Diego, CA). Study results in a total of 214 patients demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo, and a safety profile demonstrating significantly lower pruritus rates than seen with other FXR agonists.

In 2024, Organovo also demonstrated the strong potential of FXR314 in IBD, with data that showed both strong performance of FXR314 in 3D human cellular models of Crohn’s disease and ulcerative colitis. In ulcerative colitis, FXR314 broadly improved measures of epithelial barrier function and fibrotic activity in all donors, in data presented at the Crohn’s and Colitis Congress (January 25-27, Las Vegas, NV). In further studies in data presented at Digestive Disease Week (May 18-21, Washington DC), FXR314 demonstrated a combination therapeutic synergistic benefit when paired with an approved Janus kinase (JAK) inhibitor.

Organovo expects a Phase 2 study to demonstrate effectiveness of FXR314 in moderate to severe ulcerative colitis, based on effects demonstrated in preclinical animal models and its own proprietary 3D models of disease, with the possibility of development as monotherapy or combination therapy to help ulcerative colitis and Crohn’s disease patients.

About Organovo

Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic liver disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.  For more information visit Organovo’s website at www.organovo.com.

Forward Looking Statements

Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on May 31, 2024, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on November 8, 2024 and the Registration Statement on Form S-1 (File No. 333-282841). You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. 

Contact

CORE IR
[email protected]

Source: Organovo, Inc.



Posted on

Compass Diversified Holdings Announces Changes to its Board of Directors

WESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) — Compass Diversified Holdings (NYSE: CODI), an owner of leading middle market businesses, announced today that current director Gordon M. Burns advised the Board of Directors (the “Board”) on January 3, 2025, he will not be standing for re-election at the Company’s 2025 annual shareholders meeting due to other commitments. Effective as of January 3, 2025, Mr. Burns stepped down as the Chair of the Company’s Nominating & Corporate Governance Committee (the “Nominating Committee”). Mr. Burns will remain on the Company’s Board and as a member of each of the Company’s Nominating Committee and Compensation Committee up and until the Company’s 2025 annual shareholders meeting. Mr. Burns joined the Board in May of 2008.

Elias Sabo, CEO of CODI, commented: “Over the past fifteen years, Gordon has made a meaningful contribution to our Board, particularly with respect to our capital raising and capital allocation efforts. As Chair of the Board’s Nominating Committee, he was integral in identifying and recruiting the diverse and talented individuals that will lead our Board into the future. On behalf of our entire organization, I want to thank Gordon for his years of dedicated service and his many contributions to the Company.”

Effective as of January 3, 2025, current director Nancy B. Mahon has been appointed Chair of the Board’s Nominating Committee, replacing Mr. Burns.

Mahon has served as a director of the Company since May of 2023. She is currently the Chief Sustainability Officer of The Estée Lauder Companies, Inc. She holds a juris doctor degree from the New York University School of Law and is admitted to practice in both state and federal jurisdictions.

Larry Enterline, Board Chair, added: “Over the past two years, we have taken concrete steps to strengthen and diversify our Board as we prepare for the next phase of our development. Nancy, a licensed attorney, with governance expertise, brings over a decade of experience in corporate citizenship, social initiatives, and sustainability practices to her new role as Chair of our Nominating Committee. Together with our other Board members and committee chairs, we believe we are well positioned to continue to provide strong governance and oversight.”

About Compass Diversified (“CODI”)

Since its IPO in 2006, CODI has consistently executed its strategy of owning and managing a diverse set of highly defensible, middle-market businesses across the industrial, branded consumer and healthcare sectors. The Company leverages its permanent capital base, long-term disciplined approach, and actionable expertise to maintain controlling ownership interests in each of its subsidiaries, maximizing its ability to impact long-term cash flow generation and value creation. The Company provides both debt and equity capital for its subsidiaries, contributing to their financial and operating flexibility. CODI utilizes the cash flows generated by its subsidiaries to invest in the long-term growth of the Company and has consistently generated strong returns through its culture of transparency, alignment and accountability. For more information, please visit compassdiversified.com.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements with regard to the expectations related to the future performance of CODI. Words such as “believes,” “expects,” “will,” “anticipates,” “intends,” “continue,” “projects,” “potential,” “assuming,” and “future” or similar expressions, are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions, some of which are not currently known to CODI. In addition to factors previously disclosed in CODI’s reports filed with the SEC, the following factors, among others, could cause actual results to differ materially from forward-looking statements: changes in the economy, financial markets and political environment; risks associated with possible disruption in CODI’s operations or the economy generally due to terrorism, natural disasters, social, civil and political unrest or the COVID-19 pandemic; future changes in laws or regulations (including the interpretation of these laws and regulations by regulatory authorities); general considerations associated with the COVID-19 pandemic and its impact on the markets in which we operate; and other considerations that may be disclosed from time to time in CODI’s publicly disseminated documents and filings. Further information regarding CODI and factors which could affect the forward-looking statements contained herein can be found in CODI’s annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Forward-looking statements speak only as of the date they are made. Except as required by law, CODI undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations

Compass Diversified
[email protected]

Gateway Group
Cody Slach
949.574.3860
[email protected]

Media Relations

The IGB Group
Leon Berman
212.477.8438
[email protected]



Posted on

Comcast to Launch Industry-Changing, Cross-Publisher Advertising Solution for the Premium Video Category

Comcast to Launch Industry-Changing, Cross-Publisher Advertising Solution for the Premium Video Category

Universal Ads to Empower Marketers of All Sizes to Easily Purchase Scalable, Performance-Driven Video Ad Campaigns Directly from Premier Media Companies

Launch Partners Include A+E, AMC Networks, DIRECTV, Fox Corporation, NBCUniversal, Paramount, Roku, TelevisaUnivision, Warner Bros. Discovery, Xumo; Forging Groundbreaking Cross-Industry Partnerships to Strengthen the Ad Ecosystem for the Future

Set to Launch in Q1, Universal Ads is Powered by FreeWheel Technology, Which Enables Video Advertising for a Majority of Premium Video Publishers in the U.S.

NEW YORK–(BUSINESS WIRE)–
Ahead of the Consumer Electronic Show, today Comcast announced Universal Ads, a one-stop TV advertising platform that brings premier media companies together in a strategic partnership to simplify access to the premium video category. Universal Ads will allow advertisers of all sizes to buy premium video directly from some of the most prestigious media companies today at scale, as easily as they buy from social media platforms. Launching in Q1, Universal Ads is built on top of FreeWheel’s industry-leading ad technology and will seamlessly allow ad buyers and sellers to directly transact all in one place.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250106855450/en/

(Graphic: Comcast)

(Graphic: Comcast)

By strategically partnering with premium industry partners, Universal Ads will provide simplified access to scaled, qualified audiences delivered on premium content that will drive full-funnel performance for advertisers while opening new demand channels for publishers. This is Comcast’s first-ever cross-industry collaboration at this scale, with A+E, AMC Networks, DIRECTV, Fox Corporation, NBCUniversal, Paramount, Roku, TelevisaUnivision, Warner Bros. Discovery, and Xumo all committed as launch partners, and more to be announced in the coming months.

“Universal Ads has been purpose-built in response to what advertisers have been asking from Comcast. That is, make TV simpler to buy, scale and measure in a way that is compatible with the needs of performance marketers, and really, all marketers,” said James Rooke, President, Comcast Advertising. “Comcast has tremendous assets across tech, media and data. Universal Ads brings those assets together in a way that has never been done before. And, just as importantly, we are thrilled that our partners, many of whom are already FreeWheel clients, have signed on to join us in this initiative, as we seek to transform the TV ad marketplace of the future.”

According to a 2024 study of 250 performance-based advertisers conducted by Comcast Advertising, 50% of advertisers who have never advertised on TV or only done so minimally felt that their ROI from social media buying had peaked or is diminishing, and 89% are willing to try TV advertising. By building Universal Ads with an advertiser-centric approach, as an ecosystem on top of a shared technology infrastructure across publishers, performance advertisers, who were previously limited in their ability to purchase premium, brand-safe inventory from some of the top TV publishers, can now access premium video at scale directly, with a simple, consistent buying experience regardless of the publisher.

“The north star of advertising has always been combining the premium reach of linear with the precision of data-informed targeting for marketers,” said Mark Marshall, Chairman, NBCUniversal Global Advertising & Partnerships. “Now with Universal Ads, we are delivering that vision to businesses of all sizes. TV has always been a performance vehicle for brands, and Universal Ads puts the scaled reach and premium content that TV is known for into the hands of marketers everywhere.”

More specifically, Universal Ads will offer:

– Universal Ads Manager, a free self-service, easy to use TV ads buying tool.

– Direct access to premium, brand-safe video that reaches over 90% of U.S. Households.

– Plans to offer free, automated AI creative production of TV commercials.

– A marketing API, which will enable developers to build reporting, measurement, creative generation, and other applications.

“The biggest mistake TV has made is acting like it’s still 1995. SMBs want in, and they deserve to be in. The same way social democratized advertising, TV needs to drop the barriers and let brands of all sizes play at scale,” said Gary Vaynerchuk, Chairman of VaynerX, CEO of VaynerMedia, CEO of VeeFriends.

Comcast executive James Grant has been tapped to lead the Universal Ads initiative. On the product front, former Snap executive, James Borow, who helped platforms such as Snap, Reddit and Discord launch their ad businesses, has been hired to lead the Universal Ads’ product and engineering teams, in collaboration with the FreeWheel product and technology team.

According to the IAB, 75% of ads on CTV are now bought via programmatic, yet only about 20% of premium video is transacted programmatically, according to FreeWheel, due to greater complexity and guardrails that protect both brand and viewer experience. By allowing users to interact with multiple supply, data and technology partners simply, in a single, safe, ecosystem, Universal Ads would facilitate a greater percentage of media dollars to be traded programmatically in the premium video space.

“Universal Ads offers the solution to the fragmented premium video advertising category. Coming together as publishers allows us to present a singular platform for brands of any size in any category to advertise in premium video — all with the ease and familiarity of buying on social. This is a terrific opportunity for advertisers and publishers alike,” said Jeff Collins, President of Advertising Sales, Marketing and Brand Partnerships for Fox Corporation.

For more information visit www.UniversalAds.com.

About Comcast Corporation

Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit www.comcastcorporation.com for more information.

About Comcast Advertising

Comcast Advertising is the advertising division of Comcast. As a global leader in media, technology and advertising, Comcast Advertising fosters powerful connections between brands and their audiences as well as among publishers, distributors, MVPDs, agencies and other industry players. Effectv, its advertising sales division, helps local, regional and national advertisers connect with their audiences on every screen by using advanced data to drive targeting and measurement of their campaigns. FreeWheel, its media and technology arm, provides the technology, data enablement and convergent marketplaces required to ensure buyers and sellers can transact across all screens, across all data types and all sales channels, in order to ensure the ultimate goal – results for marketers. Comcast Advertising, along with NBCUniversal and Sky, is part of the Comcast Corporation (NASDAQ: CMCSA). Visit http://comcastadvertising.com/ to learn more.

About FreeWheel

FreeWheel empowers all segments of The New TV Ecosystem. We are structured to provide the full breadth of solutions the advertising industry needs to achieve their goals. We provide the technology, data enablement and convergent marketplaces required to ensure buyers and sellers can transact across all screens, across all data types, and all sales channels, in order to ensure the ultimate goal – results for marketers. With offices in New York, Chicago, London, Paris, Beijing, and across the globe, FreeWheel, A Comcast Company, stands to advocate for the entire industry through the FreeWheel Council for Premium Video. For more information, please visit https://www.freewheel.com/, and follow us on X and LinkedIn.

Media Contact

Comcast Advertising

Meredith Fitzgerald

[email protected]

215-970-8504

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Media Entertainment Search Engine Marketing Technology Digital Marketing Satellite TV and Radio Marketing Audio/Video Advertising Communications Telecommunications

MEDIA:

Logo
Logo
Photo
Photo
Universal Ads Campaign Creation (Graphic: Comcast)
Photo
Photo
(Graphic: Comcast)
Posted on

IonQ Completes Acquisition of Qubitekk, Solidifying Leadership in Quantum Networking

IonQ Completes Acquisition of Qubitekk, Solidifying Leadership in Quantum Networking

Qubitekk’s renowned technology, products, people, and patent portfolio join IonQ

IonQ expands capabilities to build the quantum internet and accelerate industry applications

COLLEGE PARK, Md.–(BUSINESS WIRE)–
IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the completion of its acquisition of substantially all of the assets of Qubitekk, Inc., a prominent quantum networking company. The acquisition brings Qubitekk’s esteemed team, advanced technology, and extensive patent portfolio into IonQ’s operations, solidifying IonQ’s position at the forefront of quantum networking and computing.

Quantum networks are poised to become important infrastructure, with the potential to drive transformative applications in sectors such as defense, finance, and energy. These networks facilitate highly secure communication between multiple quantum nodes using entangled qubits. The technology also enables precise timing synchronization, a transport layer for quantum sensing, and a backbone for distributed quantum computing. With the development and 2022 launch of the EPB Quantum Network in Chattanooga, Tennessee—the first commercially available quantum network in the U.S.—Qubitekk has established itself as a leader in quantum networking.

“The acquisition of Qubitekk is a key step in IonQ’s journey to lead quantum networking into the future,” said Jordan Shapiro, Head of Corporate Development and VP of Financial Planning & Analysis at IonQ. “Qubitekk’s innovative work in quantum networking aligns perfectly with our vision of creating scalable quantum systems that transform industries. By combining our strengths, we are not just expanding IonQ’s capabilities in critical areas like defense and cybersecurity, we expect to accelerate the development of quantum networks, the backbone of tomorrow’s quantum internet.”

IonQ has emphasized quantum networking as a strategic priority for scaling its quantum computers, as well as improving the usefulness of quantum computing in general. Its architecture plans to use photonic interconnects to link multiple quantum computers, enabling the creation of a more powerful quantum cluster. Years of investment in advancing this technology for quantum computing have positioned IonQ to make significant strides in quantum networking.

The acquisition of Qubitekk also strengthens IonQ’s customer base, creating new opportunities for bookings and revenue, and expands its quantum networking hardware and security patent portfolio to over 600 U.S. and internationally issued and pending patents with Qubitekk’s 118 U.S. and international patents.

“Joining forces with IonQ allows us to further our collective mission of making the quantum-enabled internet a near-term reality,” said Stan Ellis, Co-Founder and CEO of Qubitekk. “We are excited to become part of IonQ, bringing our quantum networking expertise to IonQ’s groundbreaking work in quantum computing.”

The Qubitekk team, including Co-Founder and CEO Stan Ellis, Co-Founder and CTO Dr. Duncan Earl, Chief Revenue Officer Corey McClelland, and President Keith Clark, has joined IonQ to advance quantum networking initiatives.

IonQ’s acquisition of Qubitekk follows closely on the heels of a series of recent quantum networking announcements from IonQ. In September, IonQ announced the largest known 2024 U.S. Quantum Contract Award of $54.5 million with United States Air Force Research Lab (AFRL) to design, develop and deliver quantum networking technology. Recently, IonQ demonstrated remote ion-ion entanglement as a key milestone towards scaling its compute across multiple quantum processors using photonic interconnects. Earlier this year, IonQ announced that it was selected by the Applied Research Laboratory for Intelligence and Security (ARLIS) for a quantum networking contract to design a first-of-its-kind, networked system for blind quantum computing. Blind quantum computing enables quantum computers to operate while remaining ‘blind’ to what information is being processed through them.

To learn more about IonQ and its latest system news and business developments, visit https://ionq.com.

Advisors

Wilson Sonsini Goodrich & Rosati served as legal counsel for IonQ.

Calabasas Capital served as financial advisor to Qubitekk.

About IonQ

IonQ, Inc. is a leader in the quantum computing and networking industry, delivering high-performance systems aimed at solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Newsweek’s 2025 Excellence Index 1000, Forbes’ 2025 Most Successful Mid-Cap Companies list, Built In’s 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.

IonQ Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “poised,” “to drive,” “plans,” “enables,” “step,” “creating,” “transform,” “accelerating,” “enabling,” “positioned,” “opportunities,” “expands,” “expanding,” “further,” “develop,” “advance,” “design,” “deliver,” “vision,” “mission,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the future significance and capabilities of quantum networks, the future creation of transformative quantum systems, accelerated development of quantum networks, the creation of a quantum internet, IonQ’s vision, mission, and strategy related to quantum networking and quantum systems, the expansion of IonQ’s expertise, capabilities and technologies, IonQ’s expansion into the quantum networking market, expectations for IonQ bookings and revenue, the expected contributions to IonQ from former Qubitekk employees, and IonQ’s future market position. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: our ability to manage our growth, including integrating acquisitions, effectively; the high competitiveness of the quantum industry; any disruptions and other problems with our facilities, operations including research and development, or test systems; IonQ’s ability to attract and retain its key employees and other personnel with specialized knowledge; any inadequacies in the overall pace of technology development in the quantum industry, including inadequate advances in the state of quantum networking and quantum systems; IonQ’s and the industry’s reliance on continued investment by the public and private sectors in developing quantum networks and systems; development of the quantum industry in ways that don’t require IonQ quantum systems or networks; IonQ’s relatively limited history in development quantum networks; IonQ’s failure to achieve quantum advantage; our ability to successfully execute our strategy; our ability to convert opportunities into bookings and revenue; the capability of our quantum systems and quantum networks to provide transformative applications and quantum advantage; changes in laws and regulations affecting IonQ, its assets or the quantum sector generally; IonQ’s ability to implement its technical roadmap; and IonQ’s ability to maintain or obtain patent protection for its products and technology. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.

IonQ Media contact:

Jane Mazur

[email protected]

IonQ Investor Contact:

[email protected]

KEYWORDS: Maryland United States North America

INDUSTRY KEYWORDS: Technology Semiconductor Security Software Networks Government Technology Internet Hardware Defense

MEDIA:

Logo
Logo
Posted on

Hologic Completes Acquisition of Gynesonics, Inc.

Hologic Completes Acquisition of Gynesonics, Inc.

MARLBOROUGH, Mass.–(BUSINESS WIRE)–
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women’s health, for approximately $350 million.

“We are excited to complete the acquisition of Gynesonics and to increase access to their Sonata® System, which complements and expands our range of minimally invasive solutions for heavy periods and fibroids,” said Brandon Schnittker, President of Surgical Solutions at Hologic. “As global champions for women’s health, we are dedicated to empowering surgeons with diverse, cutting-edge treatment options as we strive to transform women’s lives for the better.”

The Sonata System is a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. The technology combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.

“As we embark on this new phase with Hologic, we are excited to see the continued success of the Sonata System, which has already made a difference in the lives of thousands of women,” said Skip Baldino, President and Chief Executive Officer of Gynesonics. “Hologic’s commitment to women’s health and their leadership in innovation make them a perfect fit for our organization.”

About Hologic

Hologic, Inc. is a global leader in women’s health, dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. For more information on Hologic, visit www.hologic.com and connect with us on LinkedIn, Facebook, X (Twitter), Instagram and YouTube.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about Hologic’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; strategies, positioning, resources, capabilities and expectations for future performance; and financial outlook and other guidance. These forward-looking statements are based upon assumptions made as of this date and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

Risks and uncertainties that could adversely affect Hologic’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the possibility that the anticipated benefits from the transaction or products cannot be fully realized or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Gynesonics’ operations with those of Hologic will be greater than expected; the coverage and reimbursement decisions of third-party payers and the guidelines, recommendations, and studies published by various organizations relating to the use of products and treatments; the ability to successfully manage ongoing organizational and strategic changes, including Hologic’s ability to attract, motivate and retain key employees; the development of new competitive technologies and products; regulatory approvals and clearances for products; the anticipated development of markets in which products are sold into and the success of products in these markets; the anticipated performance and benefits of products; estimated asset and liability values; anticipated trends relating to Hologic’s financial condition or results of operations; and Hologic’s capital resources and the adequacy thereof.

The risks included above are not exhaustive. Other factors that could adversely affect Hologic’s business and prospects are described in Hologic’s filings with the SEC. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Hologic, The Science of Sure, Gynesonics and Sonata are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Source: Hologic, Inc.

Media Contact

Bridget Perry

Senior Director, Corporate Communications

(+1) 508.263.8654

[email protected]

Investor Contact

Michael Watts

Corporate Vice President, Investor Relations

(+1) 858.410.8514

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Software Research General Health Radiology Oncology Consumer Technology Medical Devices Artificial Intelligence Health Technology Science Women Health

MEDIA:

Logo
Logo